Daniël is an Engagement Manager with HTANALYSTS,  specialising in reimbursement submissions and health economic modelling for pharmaceuticals, diagnostics, and medical technologies. 

Daniël is currently an Engagement Manager at HTANALYSTS, specialising in reimbursement submissions and health economic modelling for pharmaceuticals, diagnostics, and medical technologies. He has led submissions to PBAC, MSAC, and Pharmac, including high-impact therapies and diagnostic technologies across multiple therapeutic areas. 

His experience includes managing reimbursement submissions, developing cost-effectiveness models, and delivering impact and feasibility studies to support payer decision-making and market access strategy. Daniël has worked across oncology and haematology, cardiovascular and pulmonary diseases, autoimmune and inflammatory diseases, endocrine and metabolic disorders, gastroenterology and hepatology, and women’s health. 

Prior to joining HTANALYSTS, Daniël was a Senior Strategy Consultant at AlphaBeta Australia (acquired by Accenture Strategy), where he delivered economic evaluations, impact studies, and market access strategies for Australian and international healthcare organisations. He also provided strategic and public policy advice to Commonwealth and State governments. 

Daniël holds a PhD in Pharmaceutical Sciences from Monash University and Bachelor and Master of Science degrees in Pharmacy from Utrecht University, and combines rigorous health economic analysis with strategic insight to support evidence-based decision-making.